Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016 - 2017)
Niagen Bioscience's (NAGE) quarterly Liabilities from Discontinued Operations came in at 215000.0 in Q4 2017, up 16.36% year-on-year from 184766.0 in Q4 2016, and little changed on a QoQ basis from 215000.0 in Q3 2017.
Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016 - 2017) Analysis & Trends
Niagen Bioscience (NAGE) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 215000.0 in Q4 2017.
- On a quarterly basis, Liabilities from Discontinued Operations rose 16.36% year-over-year to 215000.0 in Q4 2017; TTM through Dec 2017 was 215000.0, a 16.36% increase from a year earlier, with the FY2017 full-year figure at 215000.0, up 16.36% from the prior year.
- Liabilities from Discontinued Operations for Q4 2017 stood at 215000.0, roughly flat from 215000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for NAGE reached as high as 215000.0 in Q3 2017 and fell as low as 184766.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Niagen Bioscience | 253.47 Mn | 186.92 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 30, 2017 | 215,000.00 |
| Dec 30, 2017 | 215,000.00 |
| Sep 30, 2017 | 215,000.00 |
| Sep 30, 2017 | 215,000.00 |
| Dec 31, 2016 | 184,766.00 |
| Dec 31, 2016 | 184,766.00 |